Last reviewed · How we verify
Basal Bolus
Basal Bolus is an insulin regimen that mimics physiological insulin secretion by combining long-acting basal insulin with rapid-acting bolus insulin at meals.
Basal Bolus is an insulin regimen that mimics physiological insulin secretion by combining long-acting basal insulin with rapid-acting bolus insulin at meals. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus (when requiring intensive insulin therapy).
At a glance
| Generic name | Basal Bolus |
|---|---|
| Also known as | Lantus (insulin glargine), Apidra (insulin glulisine), Glargine (Lantus) + aspart (Novolog) or lispro (Humalog) |
| Sponsor | University of Campania Luigi Vanvitelli |
| Drug class | Insulin regimen |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
This regimen uses a long-acting insulin (basal) administered once or twice daily to provide baseline glucose control, combined with rapid-acting insulin (bolus) given before meals to cover carbohydrate intake. This approach approximates the body's natural insulin secretion pattern, with continuous background insulin and meal-related spikes.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus (when requiring intensive insulin therapy)
Common side effects
- Hypoglycemia
- Weight gain
- Injection site reactions
- Lipodystrophy
Key clinical trials
- Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes (PHASE2)
- Impact of Pleth Variability Index-Guided Acute Normovolemic Hemodilution on Intraoperative Fluid Management and Postoperative Complications in Cardiac Surgery (NA)
- Superficial Parasternal Intercostal Plane Block in Cardiac Surgery Trial (NA)
- Oral Anti Diabetic Agents in the Hospital (PHASE4)
- Relapse Among Diabetic Ketoacidosis Patients Maintained Basal Bolus Insulin Administration in Combination With Continuous Intravenous Insulin Infusion VS Non Maintaining Basal Insulin Patients (NA)
- A Randomized Trial Evaluating Control-IQ+ Technology in Adults With Type 2 Diabetes (NA)
- Postprocedural Contrast Mediated FFR Plus Intracoronary Infusion of Nitroglycerin in Multivessel Patients (PROMETEUS TRIAL) (NA)
- Comparison of Cumulative Opioid Consumption Between Variable-Rate Feedback Infusion and Fixed-Rate Basal Infusion Modes of Intravenous PCA Following Mixed Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Basal Bolus CI brief — competitive landscape report
- Basal Bolus updates RSS · CI watch RSS
- University of Campania Luigi Vanvitelli portfolio CI